Members Login
Medical News Feed
EPG Search
Frequent Searches:
Browse Other Languages
Spanish Drug Data (España)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
YouTube - Featured Content
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Are you a Doctor or Healthcare Professional? Authorise Viewing
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Change language
Current language database:
United Kingdom
Drug details for : ZERIDAME SR Prolonged Release Tablets
| Drug class description : | Analgesics, other opioids |
| Generic Name : | Tramadol |
| Drug description : | Prolonged-release tablet. Zeridame SR 100mg Prolonged Release Tablets are off white, round biconvex tablets, 9.1 mm diameter. Zeridame SR 150mg Prolonged Release Tablets are off white, capsule shaped tablets, 14.3 mm long. Zeridame SR 200mg Prolonged Release Tablets are off white, capsule shaped tablets 17.1 mm long. |
| Presentation : | Zeridame SR 100mg Prolonged Release Tablets - One prolonged-release tablet contains 100mg tramadol hydrochloride. Zeridame SR 150mg Prolonged Release Tablets - One prolonged-release tablet contains 150mg tramadol hydrochloride. Zeridame SR 200mg Prolonged Release Tablets - One prolonged-release tablet contains 200mg tramadol hydrochloride. |
| Indications : | Treatment of moderate to severe pain. |
| Adult Dosage : | Route of Administration Oral use Posology The dose should be adjusted to the severity of the pain and the individual clinical response of the patient. For doses not realisable / practicable with this medicinal product, other strengths of this medicinal product are available. Unless otherwise prescribed, Zeridame SR Prolonged Release Tablets should be given as follows: Adults and adolescents older than 12 years: The usual initial dose is 100mg, twice daily, in the morning and evening. Dependent upon the needs of the patient, subsequent doses may be administered earlier than 12 hours, but must not be administered earlier than 8 hours after the previous dose. Under no circumstances should more than two doses be taken in any one 24 hour period. If the painkilling is insufficient, the dose may be increased to: 150mg, twice daily or 200mg, twice daily. Zeridame SR Prolonged Release Tablets should be swallowed completely, without breaking or chewing, independent of meals, with sufficient liquid. The smallest effective analgesic dose should always be used. Daily doses of 400 mg of active substance must not be exceeded, unless exceptional medical reasons require so. Under no circumstances should Zeridame SR be used for longer than absolutely necessary. If long-term pain treatment with tramadol is necessary in view of the nature and severity of the illness, then careful and regular monitoring should be carried out (if necessary with breaks in treatment) to establish whether, and to what extent, further treatment is necessary. Renal impairment, dialysis and hepatic impairment In patients with serious renal or hepatic impairment the use of Zeridame SR is not recommended. In moderate cases, an adjustment of the dosage interval may be considered. |
| Child Dosage : | Zeridame SR is not suitable for children under the age of 12 years. |
| Elderly Dosage : | As a rule adjustment of the dose, in elderly patients (up to 75 years) without any clinical manifestations of hepatic or renal impairment, is not necessary. In elderly patients (over 75 years) elimination may be prolonged. Therefore, if necessary the dosage interval is to be extended according to the patient's requirements. |
| Contra Indications : | Zeridame SR Prolonged Release Tablets must not be used in: - hypersensitivity to tramadol hydrochloride, or to any of the excipients in the medicinal product, - in acute intoxication with alcohol, hypnotics, analgesics, opioids or psychotropic drugs. in patients receiving MAO – inhibitors, or within 2 weeks of their withdrawal. - in patients with epilepsy not adequately controlled by treatment Zeridame SR Prolonged Release Tablets should not be used for opioid withdrawal treatment. |
| Special Precautions : | Zeridame SR should only be used following a strict benefit – risk evaluation and appropriate precautionary measures in the following cases: in patients dependent on opioids, patients suffering head injuries, shock, decreased level of consciousness of unknown origin, disturbances of the respiratory centre or function, or increased intracranial pressure, patients with moderate to severe impaired liver or kidney function. Zeridame SR should not be used in combination with alcohol. In patients sensitive for opioids the medicine should be used cautiously. Convulsions have been reported at therapeutic doses and the risk may be increased at doses exceeding the usual upper daily dose limit (400 mg). The risk on convulsions may increase in patients taking tramadol and concomitant medication that can lower the seizure threshold. (See Interaction). Patients with a history of epilepsy or those susceptible to seizures should only be treated with tramadol if there are compelling reasons. Tramadol has a low dependence potential. On long-term use tolerance, psychic and physical dependence may develop. In patients with a tendency to drug abuse or dependence, treatment should be for short periods under strict medical supervision. Tramadol is not a suitable substitute in opioid dependent patients. The product does not suppress morphine withdrawal symptoms although it is an opioid agonist. |
| Interactions : | Tramadol / MAO – inhibitors Zeridame SR should not be combined with MAOinhibitors (See Contraindications). Life threatening interactions affecting the central nervous system as well as respiratory and cardiovascular function have been observed in patients who have been treated with MAO inhibitors within 14 days prior to the administration of the opioid pethidine. The same interactions with Zeridame SR as with MAO inhibitors cannot be ruled out. Tramadol / Other centrally acting active substances In concomitant use of Zeridame SR and other centrally acting drugs, including alcohol, a potentiation of CNS effects should be taken into consideration (See Adverse Reactions). Tramadol / Enzyme inhibitor / inducer The results of pharmacokinetic research, so far, showed that no interactions need to be expected in concomitant or prior use of cimetidine (enzyme inhibitor). The concomitant or prior use of carbamazepine (enzyme inducer) may reduce the analgesic effectiveness and shorten the duration of the action. Tramadol / Mixed opioid agonists / antagonists The combination of mixed agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) and tramadol is not recommended because it is theoretically possible that the analgesic effect of a pure agonist is attenuated under these circumstances. Tramadol / Seizure threshold lowering drugs Tramadol may induce convulsions and may increase the potential for selective serotonin re-uptake inhibitors, tricyclic antidepressants, anti-psychotics and other seizure threshold lowering drugs to cause convulsions. Tramadol / Serotonergic agents Isolated cases of serotonergic syndrome have been reported with the therapeutic use of tramadol in combination with other serotonergic agents such as selective serotonin re-uptake inhibitors (SSRIs). Serotonergic syndrome can be manifested by symptoms such as confusion, restlessness, fever, sweating, ataxia, hyperreflexia, myoclonia and diarrhoea. Withdrawal of the serotonergic agent produces a rapid improvement. It depends on the nature and severity of symptoms whether medicinal treatment is to be considered. Tramadol / Coumarin derivatives Caution should be exercised during concomitant treatment with tramadol and coumarin derivatives (e.g. warfarin) due to reports of increased INR and ecchymoses in some patients. Tramadol / CYP3A4 Inhibitors Other medicinal products with a known inhibiting effect on CYP3A4, such as ketoconazole and erythromycin, could inhibit the metabolism of tramadol (N-demethylation) and probably also the metabolism of the active O-demethyl-metabolite. The clinical relevancy of this interaction has not been investigated. (See Adverse Reactions). Tramadol / Ondansetron In a limited number of studies the pre – or postoperative application of the antiemetic 5 – HT3 antagonist ondansetron increased the requirement of tramadol in patients with postoperative pain. Pregnancy and lactation: Animal tests with very large concentrations of tramadol showed effects on the development of the organs, bone formation and mortality of the neonate. Teratogenic effects have not been found. Tramadol crosses the placenta, insufficient experience is available on the chronic use of tramadol during pregnancy. The repeated administration of tramadol during pregnancy can lead to increased tolerance of tramadol in the foetus and consequently to withdrawal symptoms in the new borne infant after birth, as a consequence of habituation. Therefore Zeridame SR should not be used during pregnancy. Tramadol – administered before or during birth – does not affect uterine contractility. In neonates it may induce changes in the respiratory rate which are usually not clinically relevant. When breastfeeding about 0.1 % of the tramadol dose administered is excreted in milk. Administration of Zeridame SR is not advised while breastfeeding. In case of a once only administration of tramadol it is usually not required to discontinue breastfeeding. |
| Adverse Reactions : | The most commonly reported adverse drug reactions are nausea and dizziness, both occurring in > 1 / 10 of patients, very common. Cardiovascular disorders: Uncommon (> 1 / 1000 to 1 / 100): effects on cardiovascular regulation (palpitation, tachycardia, postural hypotension or cardiovascular collapse). These adverse effects may occur especially on intravenous administration and in patients who are physically stressed. Rare (> 1 / 10000 to < 1 / 1000): bradycardia, increase in blood pressure. Nervous system disorders: Very common (> 1 / 10): dizziness Common (> 1 / 100 to < 1 / 10): headache, drowsiness Rare (>1 / 10000 to < 1 / 1000): changes in appetite, paraesthesia, tremor, respiratory depression, epileptiform convulsions, involuntary muscle contractions, and syncope. If the recommended doses are considerably exceeded and other centrally depressant substances are administered concomitantly (See Interactions) respiratory depression may occur. Epileptiform convulsions occurred mainly after administration of high doses of tramadol or after concomitant treatment with drugs, which can lower the seizure threshold or themselves induce cerebral convulsions (See Special Precautions and Interactions) Psychiatric disorders: Rare (> 1 / 10000 to < 1 / 1000): hallucinations, confusion, anxiety, sleep distubances and nightmares. Psychic side-effects may vary individually in intensity and nature (depending on personality and duration of medication). These include changes in mood (usually elation, occasionally dysphoria), changes in activity (usually suppression, occasionally increase) and changes in cognitive and sensorial capacity (e.g. decision behaviour, perception disorders). Dependence, abuse and addiction may occur. Eye disorders: Rare (> 1 / 10000 to < 1 / 1000): blurred vision Respiratory disorders: Worsening of asthma has also been reported, though a causal relationship has not been established. Gastrointestinal disorders: Very common (> 1 / 10): nausea Common (> 1 / 100 to < 1 / 10): vomiting, constipation, dry mouth. Uncommon (> 1 / 1000 to < 1 / 100): Retching, gastrointestinal irritation (a feeling of pressure in the stomach, bloating). Skin and subcutaneous tissue disorders: Common (> 1 / 100 to < 1 / 10): sweating Uncommon (> 1 / 1000 to < 1 / 100): dermal reactions (e.g. pruritus, rash, urticaria) Musculoskeletal disorders: Rare (> 1 / 10000 to < 1 / 1000): motorial weakness Hepato-biliary disorders: Very rare (< 1 / 10000) an increase in liver enzyme values has been reported after use of tramadol. Renal and urinary system disorders: Rare (> 1 / 10000 to < 1 / 1000): micturition disorders (difficulty in passing urine and urinary retention). Immune system disorders: Rare (> 1 / 10000 to < 1 / 1000): Allergic reactions (e.g. dyspnoea, bronchospasm, wheezing, angioneurotic oedema) and anaphylaxis; General disorders: Common (> 1 / 100 to < 1 / 10): fatigue. Physical Dependence Dependence, abuse, addiction, and withdrawal reactions may occur. Symptoms which occur on withdrawal, identical to withdrawal symptoms in opioids, may be: agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastro intestinal symptoms. Very rare (< 1 / 10000) atypical withdrawal symptoms have been reported: panic attack, severe anxiety, hallucinations, paraesthesia, tinnitus, and other unusual central nervous system symptoms. |
| Manufacturer : | Actavis |
| Drug Availability : | (POM) |
Free registration to access disease diagnosis, patient management, physician tools.
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org